Kala Pharmaceuticals Inc. (NASDAQ:KALA) went down by -9.83% from its latest closing price compared to the recent 1-year high of $14.68. The company’s stock price has collected -13.63% of loss in the last five trading sessions. Press Release reported on 04/28/21 that Kala Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call
Is It Worth Investing in Kala Pharmaceuticals Inc. (NASDAQ :KALA) Right Now?
Plus, the 36-month beta value for KALA is at 0.43. Opinions of the stock are interesting as 6 analysts out of 7 who provided ratings for Kala Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $20.71. KALA currently public float of 55.43M and currently shorts hold a 18.00% ratio of that float. Today, the average trading volume of KALA was 2.18M shares.
KALA’s Market Performance
KALA stocks went down by -13.63% for the week, with a monthly drop of -1.97% and a quarterly performance of -9.01%, while its annual performance rate touched -27.62%. The volatility ratio for the week stands at 6.47% while the volatility levels for the past 30 days are set at 6.11% for Kala Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is -7.04% for KALA stocks with a simple moving average of -12.86% for the last 200 days.
Analysts’ Opinion of KALA
Many brokerage firms have already submitted their reports for KALA stocks, with Jefferies repeating the rating for KALA by listing it as a “Hold.” The predicted price for KALA in the upcoming period, according to Jefferies is $10 based on the research report published on September 14th of the previous year 2020.
Oppenheimer gave a rating of “Outperform” to KALA, setting the target price at $21 in the report published on June 01st of the previous year.
KALA Trading at -7.77% from the 50-Day Moving Average
After a stumble in the market that brought KALA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.52% of loss for the given period.
Volatility was left at 6.11%, however, over the last 30 days, the volatility rate increased by 6.47%, as shares sank -3.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.73% lower at present.
During the last 5 trading sessions, KALA fell by -13.63%, which changed the moving average for the period of 200-days by -36.46% in comparison to the 20-day moving average, which settled at $7.48. In addition, Kala Pharmaceuticals Inc. saw 2.80% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at KALA starting from Bazemore Todd, who purchase 40 shares at the price of $7.60 back on Oct 22. After this action, Bazemore Todd now owns 42 shares of Kala Pharmaceuticals Inc., valued at $304 using the latest closing price.
Bazemore Todd, the Chief Operating Officer of Kala Pharmaceuticals Inc., purchase 2 shares at $13.39 during a trade that took place back on Jun 05, which means that Bazemore Todd is holding 2 shares at $27 based on the most recent closing price.
Stock Fundamentals for KALA
Current profitability levels for the company are sitting at:
- -1512.59 for the present operating margin
- +50.13 for the gross margin
The net margin for Kala Pharmaceuticals Inc. stands at -1639.85. The total capital return value is set at -58.01, while invested capital returns managed to touch -63.43. Equity return is now at value -87.60, with -43.90 for asset returns.
Based on Kala Pharmaceuticals Inc. (KALA), the company’s capital structure generated 100.92 points at debt to equity in total, while total debt to capital is 50.23. Total debt to assets is 45.54, with long-term debt to equity ratio resting at 99.39. Finally, the long-term debt to capital ratio is 49.47.
When we switch over and look at the enterprise to sales, we see a ratio of 47.55, with the company’s debt to enterprise value settled at 0.33. The receivables turnover for the company is 0.55 and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.71.